Cefpodoxime has been assigned to pregnancy category B by the FDA. Animal studies failed to reveal evidence of embryotoxicity or teratogenicity. There are no controlled data in human pregnancy. Cefpodoxime should only be given during pregnancy when need has been clearly established.

See references

Cefpodoxime is excreted into human milk in small amounts. Adverse effects in the nursing infant are unlikely. Other cephalosporins have been classified as compatible with breast-feeding by the American Academy of Pediatrics.

See references